Physician profile
Jonathan Lane
NPI 1427029206
$676.29
in general payments reported to CMS, 2019-2025
16 companies · $75.78 in 2025
The $75.78 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $146 · 2021: $59.43 · 2022: $47.89 · 2023: $105 · 2024: $89.85 · 2025: $75.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $101.60 | 2020-2025 | |
| Sobi, INC | $91.75 | 2019-2023 | |
| Pfizer INC. | $78.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $66.78 | 2021-2024 | Bexsero, Rotarix |
| Adlon Therapeutics L.P. | $42.66 | 2019-2020 | |
| Novo Nordisk INC | $32.94 | 2025 | |
| Merck Sharp & Dohme LLC | $31.31 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $29.36 | 2019-2020 | |
| Kyowa Kirin, INC. | $21.98 | 2025 | |
| Neos Therapeutics, Lp | $21.00 | 2019 | |
| Shire North American Group INC | $19.28 | 2019 | |
| Mylan Specialty L.P. | $19.26 | 2024 | Yupelri |
| Supernus Pharmaceuticals, INC. | $15.84 | 2024 | Qelbree |
| Tris Pharma INC | $14.49 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.